Health Care·Life Sciences Tools & Services·$32.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.59 | N/A | +7.06% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.59 | N/A | +7.06% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management expressed confidence in the company's strategic direction. They emphasized their commitment to enhancing product offerings.
Management highlighted strong performance in key segments.
They noted ongoing investments in innovation to drive future growth.
Agilent Technologies reported better-than-expected earnings per share, indicating solid operational performance. However, the stock fell slightly by 0.4%, possibly due to the lack of revenue data and guidance, which left investors uncertain about future growth prospects.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
COMPANHIA DE SANEAME ADR
Aug 14, 2017